Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Mesenchymal stem cell treatment for IPF-time for phase 2 trials?

Antoniou KM, Karagiannis K, Tsitoura E, Tzanakis N.

Lancet Respir Med. 2017 Jun;5(6):472-473. doi: 10.1016/S2213-2600(17)30180-7. Epub 2017 May 26. Review. No abstract available.

PMID:
28664848
2.

Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment.

Liu M, Ren D, Wu D, Zheng J, Tu W.

Curr Stem Cell Res Ther. 2015;10(6):466-76. Review.

PMID:
25986617
3.

Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.

Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM.

Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24.

4.

Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.

Toonkel RL, Hare JM, Matthay MA, Glassberg MK.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):133-40. doi: 10.1164/rccm.201207-1204PP. Review.

PMID:
23306542
5.

Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease.

Ghadiri M, Young PM, Traini D.

Expert Opin Biol Ther. 2016;16(3):375-87. doi: 10.1517/14712598.2016.1124085. Epub 2015 Dec 15. Review.

PMID:
26593230
6.

Moving stem cell therapy to patients with idiopathic pulmonary fibrosis.

Glassberg MK, Toonkel RL.

Respirology. 2014 Oct;19(7):950-1. doi: 10.1111/resp.12364. Epub 2014 Aug 14. No abstract available.

7.

Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell.

Choi M, Ban T, Rhim T.

Mol Cells. 2014 Feb;37(2):133-9. doi: 10.14348/molcells.2014.2317. Epub 2014 Feb 19.

8.

Cell therapy trials for lung diseases: progress and cautions.

Weiss DJ, Ortiz LA.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):123-5. doi: 10.1164/rccm.201302-0351ED. No abstract available.

9.

A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis.

Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM.

Respirology. 2014 Oct;19(7):1013-8. doi: 10.1111/resp.12343. Epub 2014 Jul 9.

10.

Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis.

Tzouvelekis A, Bouros D.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):251-2. doi: 10.1164/rccm.201301-0072LE. No abstract available.

PMID:
23855695
11.

Idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.

Chambers DC, Hopkins PM.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):252-3. doi: 10.1164/rccm.201301-0192LE. No abstract available.

PMID:
23855696
12.

Reply: idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.

Glassberg MK, Hare JM, Toonkel RL, Matthay MA.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):253-4. doi: 10.1164/rccm.201302-0244LE. No abstract available.

13.

Therapeutic update in idiopathic pulmonary fibrosis.

Chan AL, Rafii R, Louie S, Albertson TE.

Clin Rev Allergy Immunol. 2013 Feb;44(1):65-74. doi: 10.1007/s12016-010-8244-9. Review.

PMID:
21222174
14.

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.

Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE Jr, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK.

Eur Respir J. 2015 Jul;46(1):243-9. doi: 10.1183/09031936.00200614. Epub 2015 Apr 21.

15.

Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.

Barczyk M, Schmidt M, Mattoli S.

Stem Cell Rev. 2015 Aug;11(4):598-620. doi: 10.1007/s12015-015-9587-7. Review.

PMID:
25896401
16.

[Idiopathic Pulmonary Fibrosis].

Prasse A.

Pneumologie. 2015 Oct;69(10):608-14; quiz 615. doi: 10.1055/s-0034-1393036. Epub 2015 Oct 7. German.

17.

Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.

Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group.

Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9. No abstract available.

PMID:
23047830
18.

Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?

Huie TJ, Brown KK.

Respir Investig. 2015 May;53(3):88-92. doi: 10.1016/j.resinv.2014.12.005. Epub 2015 Mar 4. Review.

PMID:
25951093
19.

Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D.

J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182.

20.

A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.

Vancheri C, du Bois RM.

Eur Respir J. 2013 Feb;41(2):262-9. doi: 10.1183/09031936.00115112. Epub 2012 Aug 16.

Supplemental Content

Support Center